Pathogenesis and Significance of Urogenital Mycoplasmal Infections

Cassell, G. H.; Davis, J. K.; Waites, Ken B.; Rudd, Peter; Talkington, Deborah F.; Crouse, Dennis T.; Horowitz, Shulamith

doi:10.1007/978-1-4684-8932-3_10

Cited by 27 publications

(12 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mycoplasma pneumoniae is an important cause of tracheobronchitis in school-aged children and accounts for up to 20% of all pneumonia cases in the general population (4). Mycoplasma hominis and Ureaplasma urealyticum are responsible for numerous pathologic conditions of the urogenital tract as well as other organ systems, particularly in immunosuppressed persons and newborn infants (5). Antibiotic resistance to currently available drugs in many strains of genital mycoplasmas intensifies the need to evaluate new antimicrobial agents to treat infections caused by these organisms (8,12,16).…”

mentioning

confidence: 99%

In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones

Waites

Cassell

Canupp

et al. 1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

In vitro activities of the new macrolides clarithromycin, previously designated A-56268 , and A-63075 and of the aryl-fluoroquinolones difloxacin (A-56619) and temafloxacin (A-62254) against 14 strains of Mycoplasma pneumoniae, 20 strains of Mycoplasma hominis, and 28 strains of Ureaplasma urealyticum were compared with that of erythromycin. All The number of organisms added was verified by serial tenfold dilutions of the suspension used to inoculate the assay plates (0.1 ml/0.9 ml of broth). These were incubated, and CCU per milliliter was determined to ensure that an adequate (103 CCU/ml) but not excessive (>105 CCU/ml) amount was actually inoculated into the test system. Controls included in every microdilution plate assay for each strain and drug tested were (i) a broth control without 1500 ANTIMICROBIAL

show abstract

mentioning

confidence: 99%

In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones

Waites

Cassell

Canupp

et al. 1988

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…The human mycoplasma Ureaplasma urealyticum inhabits the urogenital system of 40-80% of the sexually active population and is associated with numerous diseases in men, women and infants (non-gonococcal urethritis, pelvic inflammatory disease, chorioamnionitis, recurrent and spontaneous abortions, neonatal morbidity and mortality, and infertility) (Cassell et al, , 1987Taylor-Robinson, 1986;Hillier et al, 1988).…”

Section: Introductionmentioning

confidence: 99%

“…It has been suggested that only some of the 14 known serotypes of U. urealyticum may be pathogenic and that the others are not involved in disease (Robertson et al, 1986;Cassell et al, 1987;Naessens et al, 1988). To establish the pathogenic potential of individual serotypes requires identification of serotype-specific antigens.…”

Section: Introductionmentioning

confidence: 99%

Isolation and purification of viable Ureaplasma urealyticum cells free from medium components

Horowitz

Gal

1991

Journal of General Microbiology

View full text Add to dashboard Cite

A procedure was devised to produce Ureaplasma uredyticum preparations free of adsorbed components of the growth medium, which contains high concentrations of serum. The ureaplasmas were cultivated in a medium containing PPLO-serum fraction as a replacement for horse serum. High titres of ureaplasmas (> lo7 c.f.u. ml-l) were obtained. Harvested cells were then purified by Urograh density gradient centrifugation. By use of 3H-labelled ureaplasma cells and 251-labelled medium components, a distinct band of viable cells devoid of serum constituents was demonstrated. The absence of medium components was verified by immunoblotting cells from this band with antiserum to medium components. Medium components that had been present before the purification procedure were undetectable in the purified cell fraction obtained. The viability of the purified ureaplasma cells represented an 85 % recovery rate and their antigenicity, examined with anti-serotype specific antiserum, remained intact. This easy and reproducible procedure can be used to prepare purified ureaplasmas for investigation of ureaplasmal antigens and their expression and/or role in disease.

show abstract

“…3,4 Since resistance to traditional drugs, such as tetracycline, used for treating these infections is widely known for both U. urealyticum and M. hominis, s-9 alternative antimicrobial agents should be evaluated.…”

mentioning

confidence: 99%

In Vitro Susceptibility of Ureaplasma urealyticum and Mycoplasma hominis Isolates in Argentina

Smayevsky

Relloso

Lanza

et al. 1995

Infectious Diseases in Obstetrics and Gynecology

View full text Add to dashboard Cite

Pathogenesis and Significance of Urogenital Mycoplasmal Infections

Cited by 27 publications

References 99 publications

In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones

In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones

Isolation and purification of viable Ureaplasma urealyticum cells free from medium components

In Vitro Susceptibility of Ureaplasma urealyticum and Mycoplasma hominis Isolates in Argentina

Contact Info

Product

Resources

About